Vaccines for emerging pathogens: prospects for licensure
Vaccines for emerging pathogens: prospects for licensure
复制标题
DOI：
10.1111/cei.13284
复制
发表时间：
2019-04
影响因子：
4.6
通讯作者：
E. Williamson;G. Westlake
中科院分区：
文献类型：
--
作者：
E. Williamson;G. Westlake
在全球范围内，出现了许多新出现的病原体。对大多数人来说，尽管正在进行研究和开发，但还没有可供人类使用的许可疫苗。然而，考虑到新出现的病原体清单广泛且不断增加，以及将疫苗投入临床所需的投资，任务是巨大的。在这项任务上覆盖的是微生物获得抗微生物耐药性(AMR)的风险，这可能赋予相对无害的有机体致病潜力。此外，气候变化还带来了挑战，导致热带地区流行的一些昆虫媒介和环境条件开始从这些传统地区扩散，从而增加了人畜共患病的迁移风险。
Globally, there are a number of emerging pathogens. For most, there are no licensed vaccines available for human use, although there is ongoing research and development. However, given the extensive and increasing list of emerging pathogens and the investment required to bring vaccines into clinical use, the task is huge. Overlaid on this task is the risk of anti‐microbial resistance (AMR) acquisition by micro‐organisms which can endow a relatively harmless organism with pathogenic potential. Furthermore, climate change also introduces a challenge by causing some of the insect vectors and environmental conditions prevalent in tropical regions to begin to spread out from these traditional areas, thus increasing the risk of migration of zoonotic disease.